

Substitute for form 1449A-PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

|                        |                    |
|------------------------|--------------------|
| Application Number     | 10/051,320         |
| Filing Date            | January 18, 2002   |
| First Named Inventor   | H. Michael SHEPARD |
| Art Unit               | 1646               |
| Examiner Name          | Unassigned         |
| Attorney Docket Number | NB 2019.00         |


## **U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number - Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear |
|--------------------|-----------------------|---|------------------------------|--|---|
|                    | 1                     | US-3,852,266  | 12/03/74                     | Kiyanagi et al.                                      |   |
|                    | 2                     | US-4,247,544  | 01/27/81                     | Bergstrom et al.                                     |   |
|                    | 3                     | US-4,267,171  | 05/12/81                     | Bergstrom et al.                                     |   |
|                    | 4                     | US-4,542,210  | 09/17/85                     | Sakata et al.  |   |
|                    | 5                     | US-4,816,570  | 03/28/89                     | Farquhar   |   |
|                    | 6                     | US-4,948,882  | 08/14/90                     | Ruth   |   |
|                    | 7                     | US-4,975,278  | 12/04/90                     | Senter et al.  |   |
|                    | 8                     | US-5,070,082  | 12/03/91                     | Murdock et al.                                       |   |
|                    | 9                     | US-5,077,282  | 12/31/91                     | Murdock et al.                                       |   |
|                    | 10                    | US-5,077,283  | 12/31/91                     | Murdock et al.                                       |   |
|                    | 11                    | US-5,085,983  | 02/04/92                     | Scanlon  |   |
|                    | 12                    | US-5,116,827  | 05/26/92                     | Murdock et al.                                       |   |
|                    | 13                    | US-5,212,161  | 05/18/93                     | Moriniere et al.                                     |   |
|                    | 14                    | US-5,212,291  | 05/18/93                     | Murdock et al.                                       |   |
|                    | 15                    | US-5,233,031  | 08/03/93                     | Borch et al.   |   |
|                    | 16                    | US-5,264,618  | 11/23/93                     | Felgner et al.                                       |   |
|                    | 17                    | US-5,457,187  | 10/10/95                     | Gmeiner et al.                                       |   |
|                    | 18                    | US-5,459,127  | 10/17/95                     | Felgner et al.                                       |   |
|                    | 19                    | US-5,521,161  | 05/28/96                     | Malley et al.  |   |
|                    | 20                    | US-5,616,564  | 04/01/97                     | Rapaport   |   |
|                    | 21                    | US-5,627,165  | 05/06/97                     | Glazier  |   |
|                    | 22                    | US-5,645,988  | 07/08/97                     | Vande Woude et al.                                   |   |
|                    | 23                    | US-5,663,321  | 09/02/97                     | Gmeiner et al.                                       |   |
|                    | 24                    | US-5,798,340  | 08/25/98                     | Bischofberger et al.                                 |   |
|                    | 25                    | US-5,981,507  | 11/09/99                     | Josephson et al.                                     |   |
|                    | 26                    | US-6,245,750 B1   | 06/12/01                     | Shepard  |   |

## **FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited Document  | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|--|------------------------------|---|--|----------------|
|                    | 27                    | GB 982,776   | 02/10/65                     | The Wellcome Foundation   |  |                |
|                    | 28                    | WO 91/17424  | 11/14/91                     | Vical, Inc.   |  |                |
|                    | 29                    | WO 93/06120 A1   | 04/01/93                     | University of Rochester   |  |                |
|                    | 30                    | WO 94/03467  | 02/17/94                     | Institute of Organic Chemistry<br>and Biochemistry of the<br>Academy of Sciences of the<br>Czech Republic |  |                |
|                    | 31                    | WO 94/22483  | 10/13/94                     | D-Pharm, Ltd.   |  |                |

|   |    |                |          |  |  |
|---|----|----------------|----------|--|--|
| ✓ | 32 | WO 95/08556    | 03/30/95 | Amersham Int'l. PLC.   |  |
|   | 33 | WO 96/03151A2  | 02/08/96 | Cancer Research Campaign Technology  |  |
|   | 34 | WO 96/07413A1  | 03/14/96 | University of Georgia Research Foundation, Inc., et al.  |  |
|   | 35 | WO 96/10030    | 04/04/96 | Isis Pharmaceuticals, Inc.   |  |
|   | 36 | WO 96/29336    | 09/26/96 | Medical Research Council, et al.   |  |
|   | 37 | WO 96/40088    | 12/19/96 | Hostetter  |  |
|   | 38 | WO 96/40708    | 12/19/96 | La Jolla Pharmaceuticals Co.   |  |
|   | 39 | WO 97/28179    | 08/07/97 | The Regents of the University of California  |  |
|   | 40 | WO 99/08110    | 02/18/99 | NewBiotics, Inc.   |  |
|   | 41 | WO 99/20741    | 04/29/99 | Geron Corporation  |  |
|   | 42 | WO 99/23104    | 05/14/99 | The Government of the United States of America represented by The Secretary of Health and Human Services |  |
|   | 43 | WO 99/37753    | 07/29/99 | NewBiotics, Inc.   |  |
|   | 44 | WO 01/07454 A1 | 02/01/01 | NewBiotics, Inc.   |  |
| ✓ | 45 | WO 01/07088 A2 | 02/01/01 | NewBiotics, Inc.   |  |



TECH CENTER 1600/2900

MAY 31 2002


RECEIVED

|                          |                             |
|--------------------------|-----------------------------|
| Examiner's Signature<br> | Date Considered<br>11/17/03 |
|--------------------------|-----------------------------|

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**+** Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

11

Application Number

10/051,320

Filing Date

January 18, 2002

First Named Inventor

H. Michael SHEPARD

Art Unit

1646

Examiner Name

Unassigned

Attorney Docket Number

NB 2019.00

TECH CENTER 1600/2300

MAY 31 2002

RECEIVED


**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published   | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
| K                     | 1                        | ABRAHAM, T.W., et al. (1996) "Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1- $\beta$ -arabinofuranosylcytosine: Evidence of phosphoramidase activity" <i>J. Med. Chem.</i> 39:4569-4575.  |                |
|                       | 2                        | AKDAS, A., et al. (1996) "Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder" <i>Eur. Urol.</i> 29:483-486.  |                |
|                       | 3                        | ALMASAN, A., et al. (1995) "Genetic instability as a consequence of inappropriate entry into and progression through S-phase" <i>Cancer &amp; Metastasis Rev.</i> 14:59-73.   |                |
|                       | 4                        | ALMASAN, A., et al. (June 1995) "Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis" <i>PNAS, USA</i> 92:5436-5440.   |                |
|                       | 5                        | ANDERSEN, T.I., et al. (1995) "Detection of c-erbB-2 related protein in sera from breast cancer patients" <i>Acta Oncol.</i> 34(4):499-504.   |                |
|                       | 6                        | ANGLADA, J.M., et al. (July-August 1996) "N,N'-cyclization of carbodiimides with 2-(bromomethyl)acrylic acid. A direct entry to the system 5-methylene-6H-pyrimidine-2,4-dione, a new class of thymine analogues" <i>J. Heterocyclic Chem.</i> 33:1259-1270.  |                |
|                       | 7                        | ANTELMAN, D., et al. (1995) "Inhibition of tumor cell proliferation <i>in vitro</i> and <i>in vivo</i> by exogenous p110 <sup>RB</sup> , the retinoblastoma tumor suppressor protein" <i>Oncogene</i> 10:697-704.   |                |
|                       | 8                        | ASAKURA, J., et al. (1988) "Cerium(IV) catalyzed iodination at C5 of uracil nucleosides" <i>Tetrahedron Lett.</i> 29(23):2855-2858.   |                |
|                       | 9                        | ASAKURA, J., et al. (1990) "Cerium(IV)-mediated halogenation at C-5 of uracil derivatives" <i>J. Org. Chem.</i> 55:4929-4933.   |                |
|                       | 10                       | ASCHELE, C. et al. (June 1999) "Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy" <i>J. Clin. Oncol.</i> 17(6):1760-1770.   |                |
|                       | 11                       | AYISI, N. K., et al. (1933) "Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5'-monophosphate with adenine arabinoside-5'-monophosphate" <i>Antiviral Res.</i> 3:161-174.  |                |
|                       | 12                       | BALZARINI, J., et al. (1987) "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene" <i>Mol. Pharmacol.</i> 32:410-416.            |                |
|                       | 13                       | BALZARINI, J., et al. (1993) "Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2" <i>J. Biol. Chem.</i> 268(9):6332-6337. |                |
|                       | 14                       | BALZARINI, J., et al. (1995) "Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line" <i>Meth. Find. Exptl. Clin. Pharmacol.</i> 7(1):19-28.   |                |
|                       | 15                       | BALZARINI, J., et al. (1996) "Anti-HIV and anti-HIV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109" <i>Biochem. Biophys. Res. Commun.</i> 225:363-369.   |                |
|                       | 16                       | BALZARINI, J., et al. (1997) "Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxy-2',3'-dideoxyadenosine (d4A) to their corresponding arylphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus" <i>FEBS Lett.</i> 410:324-328.                       |                |
|                       | 17                       | BALZARINI, J., et al. (July 1996) "Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives" <i>PNAS USA</i> 93:7295-7299.  |                |

f. Cruz 4/17/03

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|--------------------|-----------------------|---|----------------|



|  |    |  |  |
|--|----|--|--|
|  | 18 | BANERJEE, D., et al. (1995) "Molecular mechanisms of resistance to antifolates, a review" <i>Acta Biochemical Polonica</i> 42(4):457-464.  |  |
|  | 19 | BANERJEE, D., et al. (October 1998) "Role of E2F-1 in chemosensitivity" <i>Can. Res.</i> 58:4292-4296.   |  |
|  | 20 | BARBATO, S., et al. (1989) "Synthesis of bridged pyrimidine nucleosides and triazo [4, 3-c] pyrimidine nucleoside analogues" <i>Nucleosides &amp; Nucleotides</i> 8(4):515-528.  |  |
|  | 21 | BARBOUR, K.W., et al. (1992) "A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells" <i>Mol. Pharmacol.</i> 42:242-248.  |  |
|  | 22 | BARR, P.J., et al. (1981) "Inhibition of thymidylate synthetase by 5-alkynyl-2'-deoxyuridylates" <i>J. Med. Chem.</i> 24(12):1385-1388.  |  |
|  | 23 | BARR, P.J., et al. (1983) "Reaction of 5-ethynyl-2'-deoxyuridylate with thiols and thymidylate synthetase" <i>Biochem.</i> 22:1696-1703.   |  |
|  | 24 | BARR, P.J., et al. (1983) "Thymidylate synthetase-catalyzed conversions of E-5-(2-Bromovinyl)-2'-deoxyuridylate" <i>J. Biol. Chem.</i> 258(22):13627-13631.  |  |
|  | 25 | BARRETT, J.E., et al. (1998) "Trapping of the C5 methylene intermediate in thymidylate synthase" <i>J. Am. Chem. Soc.</i> 120:449-450.   |  |
|  | 26 | BELT, J.A., et al. (1993) "Nucleoside Transport in Normal and Neoplastic Cells" <i>Advan. Enzyme Regul.</i> 33:235-252.  |  |
|  | 27 | BENZARIA, S., et al. (1996) "Synthesis, <i>in vitro</i> antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability" <i>J. Med. Chem.</i> 39:4958-4965.    |  |
|  | 28 | BERGSTROM, D.E., et al. (1981) "C-5 substituted pyrimidine nucleosides. 3. Reaction of allylic chlorides, alcohol, and acetates with pyrimidine nucleoside derived organopalladium intermediates" <i>J. Org. Chem.</i> 46(7):1432-1441.  |  |
|  | 29 | BERGSTROM, D.E., et al. (1984) "Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1" <i>J. Med. Chem.</i> 27:279-284. |  |
|  | 30 | BERTINO, J.R., et al. (1996) "Resistance mechanism to methotrexate in tumors" <i>Stem Cells</i> 14:5-9.  |  |
|  | 31 | BERKOW, R., et al. (1992) "The Merck Manual of Diagnosis and Therapy" 16 <sup>th</sup> Edition, Merck & Co., Rahway, New Jersey, p. 1278.  |  |
|  | 32 | BIBLE, K.C. et al. (August 15, 1997) "Cytotoxic Surgery between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration" <i>Cancer Res.</i> 57:3375-3380.  |  |
|  | 33 | BIGGE, C.F., et al. (1980) "Palladium-catalyzed coupling reactions of uracil nucleosides and nucleosides" <i>J. Am. Chem. Soc.</i> 102(6):2033-2038.   |  |
|  | 34 | BOSSLET, K., et al. (1995) "A novel one-step tumor-selective prodrug activation system" <i>Tumor Targeting</i> 1:45-50.  |  |
|  | 35 | BOSSLET, K., et al. (March 15, 1998) "Elucidation of the mechanism enabling tumor selective prodrug monotherapy" <i>Cancer Res.</i> 58:1195-1201.  |  |
|  | 36 | BRISON, O. (1993) "Gene amplification and tumor progression" <i>Biochem. Biophys. Acta</i> 1155:25-41.   |  |
|  | 37 | BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 <sup>th</sup> Edition Doxifluridine, page 3493.   |  |
|  | 38 | BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 <sup>th</sup> Edition Floxuridine, page 4148.   |  |
|  | 39 | BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 <sup>th</sup> Edition Idoxuridine, page 4934.   |  |
|  | 40 | CARL, P.L., et al. (1980) "Protease-activated 'prodrugs' for cancer chemotherapy" <i>PNAS USA</i> 77(4):2224-2228.   |  |
|  | 41 | CARRERAS, C.W., et al. (1995) "The catalytic mechanism and structure of thymidylate synthase" <i>Annu. Rev. Biochem.</i> 64:721-762.   |  |
|  | 42 | CARTER, P., et al. (May 1992) "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy" <i>PNAS USA</i> 89:4285-4289.   |  |
|  | 43 | CAVA, M.P., et al. (1985) "Thionation reactions of lawesson's reagents" <i>Tetrahedron</i> 41(22):5061-5087.   |  |
|  | 44 | CHAKRAVARTY, P.K., et al. (1983) "Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin" <i>J. Med. Chem.</i> 26(5):638-644.   |  |
|  | 45 | CHAUDHURI, N.C., et al. (1995) "Very high affinity DNA recognition by bicyclic and cross-linked oligonucleotides" <i>J. Am. Chem. Soc.</i> 117:10434-10442.  |  |
|  | 46 | CHEN, L., et al. (March 15, 1996) "Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene" <i>Can. Res.</i> 56:1331-1340.   |  |


TECH CENTER 1600/2900

MAY 31 2002

*[Signature]* 11/18/03

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T² |
|--------------------|-----------|---|----|
|--------------------|-----------|---|----|



TECH CENTER (001/2002)


MAY 3 2002

RECEIVED

|    |  |   |  |
|----|--|---|--|
| 47 |  | CHO, Y.M., et al. (1994) "(E)-5-(3-oxopropen-1-yl)-2'-deoxyuridine and (E)-5-(3-oxopropen-1-yl)-2',3'-dideoxyuridine; new antiviral agents: Syntheses and biological activity" <i>Tetrahedron Lett.</i> 35(8):1149-1152.  |  |
| 48 |  | CHOU, T.C., et al. (1984) "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors" <i>Adv. Enzyme Regul.</i> 22:27-55.   |  |
| 49 |  | CLARKE, R., et al. (1996) "Animal models of breast cancer. Their diversity and role in biomedical research" <i>Breast Can. Res. &amp; Treatment</i> 39:1-6.   |  |
| 50 |  | COLACINO, J.M. (1996) "Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)" <i>Antiviral Res.</i> 29:125-139.   |  |
| 51 |  | COLLINS, J.M., et al. (August 1999) "Suicide Prodrugs Activated by Thymidylate Synthase: Rationale for Treatment and Noninvasive Imaging of Tumors with Deoxyuridine Analogues" <i>Clin. Cancer Res.</i> 5:1976-1981.   |  |
| 52 |  | CONNORS, T.A. (1986) "Prodrugs in cancer chemotherapy" <i>Xenobiotica</i> 16(10/11):975-988.  |  |
| 53 |  | CONNORS, T.A. (1996) "Is there a future for cancer chemotherapy" <i>Annals Oncol.</i> 7:445-452.  |  |
| 54 |  | CONNORS, T.A., et al. (1995) "Prodrugs in cancer chemotherapy" <i>Stem Cells</i> 13:501-511.  |  |
| 55 |  | COPUR, S., et al. (1995) "Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil" <i>Biochem. Pharmacol.</i> 49(10):1419-1426.  |  |
| 56 |  | CRISP, G.T. (1989) "Synthesis of 5-alkenyl-2'-deoxyuridines via organostannanes" <i>Synthetic Commun.</i> 19(11&12):2117-2123.  |  |
| 57 |  | CRUICKSHANK, K.A., et al. (1988) "Oligonucleotide labeling: A concise synthesis of a modified thymidine phosphoramidite" <i>Tetrahedron Lett.</i> 29(41):5221-5224.   |  |
| 58 |  | CURTIN, N.J., et al. (May 1, 1991) "Mechanism of Cell Death following Thymidylate Synthase Inhibition: 2'-Deoxyuridine-5'-triphosphate Accumulation, DNA Damage, and Growth Inhibition following Exposure to CB3717 and Dipyridamole" <i>Cancer Res.</i> 51:2346-2352.  |  |
| 59 |  | DAGLE, J.M., et al. (August 25, 1990) "Targeted Degradation of mRNA in <i>Xenopus</i> oocytes and Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis" <i>Nucleic Acids Research</i> 18(16):4751-4757.  |  |
| 60 |  | DALE, R.M.K., et al. (August 1973) "The synthesis and enzymatic polymerization of nucleotides containing mercury: Potential tools for nucleic acid sequencing and structural analysis" <i>PNAS USA</i> 70(8):2238-2242.   |  |
| 61 |  | DAVISSON, V.J., et al. (1989) "Expression of human thymidylate synthase in <i>Escherichia coli</i> " <i>J. Biol. Chem.</i> 264(16):9145-9148.   |  |
| 62 |  | DAVISSON, V.J., et al. (1994) "Expression of human thymidylate synthase in <i>Escherichia coli</i> . (Additions and corrections" <i>J. Biol. Chem.</i> 269(48):30740.   |  |
| 63 |  | DE CLERCQ, E. (1994) "Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside Analogues" <i>Nucleosides &amp; Nucleosides</i> 13(6&7):1271-1295.  |  |
| 64 |  | DE CLERCQ, E., et al. (1983) "Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides" <i>J. Med. Chem.</i> 26:661-666.  |  |
| 65 |  | DE CLERCQ, E., et al. (September 18, 1978) "Antiviral Activity of Novel Deoxyuridine Derivatives" <i>Current Chemotherapy: Proceedings of the International Congress of Chemotherapy</i> 1:352-354.   |  |
| 66 |  | DE CLERCQ, E., et al. (October 1997) "In Search of a Selective Antiviral Chemotherapy" <i>Clin. Microbiol. Rev.</i> 10(4):674-693.  |  |
| 67 |  | DICKER, A.P., et al. (December 1993) "Methotrexate resistance in an <i>in vivo</i> mouse tumor due to a non-active-site dihydrofolate reductase mutation" <i>PNAS USA</i> 90:11797-11801.   |  |
| 68 |  | DIRVEN, H.A.A.M., et al. (April 15, 1995) "The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa" <i>Can. Res.</i> 55:1701-1706.   |  |
| 69 |  | DORR, R.T., et al. (1994) "PALA" In: <i>Cancer Chemotherapy Handbook</i> : Appleton & Lange, Norwalk, Connecticut: 768-773.   |  |
| 70 |  | DRAKE, J.C., et al. (1996) "Resistance to Tomudex (ZD1694): Multifactorial in Human Breast and Colon Carcinoma Cell Lines" <i>Biochem. Pharmacol.</i> 51:1349-1355.   |  |
| 71 |  | DUNN III, W.J., et al. (1996) "Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis" <i>J. Med. Chem.</i> 39:4825-4832. |  |
| 72 |  | DYER, R.L., et al., "The synthesis of E-5-(2-bromovinyl)-2'-deoxyuridine from 2'-deoxy-5-iodouridine" in: <i>Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques</i> , Townsend et al. (Eds.), John Wiley & Sons, Inc., New York, pp. 79-83. (2000)   |  |


11/17/03

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials*  | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup> |
|--|--------------------------|---|----------------|
|  | 73                       | ECCLES, S.A., et al. (1994-1995) "Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy" <i>Invasion Metastasis</i> 14:337-348.  |                |
|  |                          | EDLER, D., et al. (February 2000) "Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival" <i>Clinical Cancer Research</i> 6:488-492.   |                |
|  | 75                       | EISENBRAND, G., et al. (1996) "An approach towards more selective anticancer agents" <i>J. Synthetic Organic Chem.</i> 10:1246-1258.  |                |
|  | 76                       | EVARD, A., et al. (1996) "An in vitro nucleoside analog screening method for cancer gene therapy" <i>Chem. Abstracts</i> 126:Abstract No. 26514, Issue No. 3, p.32, January 20, 1997.   |                |
|  | 77                       | EVARD, A., et al. (1996) "An in vitro nucleoside analog screening method for cancer gene therapy" <i>Cell Biol. Toxicol.</i> 12:345-350.  |                |
|  | 78                       | FAN, J., et al. (1997) "Functional roles of E2F in cell cycle regulation" <i>Oncogene</i> 14:1191-1200.   |                |
|  | 79                       | FARQUHAR, D., et al. (1994) "Synthesis and antitumor evaluation of bis(pivaloyloxy)methyl[2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): A strategy to introduce nucleotides into cells" <i>J. Med. Chem.</i> 37:3902-3909.                               |                |
|  | 80                       | FARQUHAR, D., et al. (1995) "5'-[4-(pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: A membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP)" <i>J. Med. Chem.</i> 38:488-495.  |                |
|  | 81                       | FELIP, E., et al. (1995) "Overexpression of c-erbB-2 in epithelia ovarian cancer" <i>Cancer</i> 75(8):2147-2152.  |                |
|  | 82                       | FINCH, S.C., et al. (1991) "Radiation Injury" In: Harrison's Principles of Internal Medicine, 12 <sup>th</sup> edition: McGraw-Hill, Inc., New York, NY:2004-2208.  |                |
|  | 83                       | FINER-MOORE, J., et al. (1993) "Refined structures of substrate-bound and phosphate-bound thymidylate synthase from <i>Lactobacillus casei</i> " <i>J. Mol. Biol.</i> 232:1101-1116.  |                |
|  | 84                       | FINER-MOORE, J.S., et al. (1994) "Crystal structure of thymidylate synthase from T4 phage: Component of a deoxynucleoside triphosphate-synthesizing complex" <i>Biochem.</i> 33:15459-15468.  |                |
|  | 85                       | FIRESTONE, W.M., et al. (May 1990) "A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma" <i>J. Investigative Dermatol.</i> 94:657-661.  |                |
|  | 86                       | FIRESTONE, W.M., et al. (July 2, 1990) "A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma" <i>Chem. Abstracts</i> 113:Abstract No. 254.   |                |
|  | 87                       | FREED, J.J., et al. (1989) "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells" <i>Biochem. Pharmacol.</i> 38(19):3193-3198.                                |                |
|  | 88                       | FREEMANTLE, S.J., et al. (1995) "Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694" <i>British Journal of Cancer</i> 71:925-930.  |                |
|  | 89                       | FRIES, K.M., et al. (1995) "Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs" <i>J. Med. Chem.</i> 38(14):2672-2680.   |                |
|  | 90                       | FUNK, J.O. (1999) "Cancer cell cycle control" <i>Anticancer Research</i> 19:4772-4780.  |                |
|  | 91                       | GARRETT, C.G., et al. (1979) "Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate" <i>Biochem.</i> 18(13):2798-2804.   |                |
|  | 92                       | GOEL, R., et al. (February 1989) "Selective Intraperitoneal Biochemical Modulation of Methotrexate by Dipyrindamole" <i>J. Clin. Oncol.</i> 7(2):262-269.   |                |
|  | 93                       | GOLDBERG, J.L., et al. (1997) "Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos" <i>Am. J. Respir. Cell Mol. Biol.</i> 17:265-271.  |                |
|  | 94                       | GOLDSTEIN, J.L., et al. (1991) "Genetic aspects of disease" In: Harrison's Principles of Internal Medicine, 12 <sup>th</sup> edition: McGraw-Hill, Inc., New York, NY:21-76.  |                |
|  | 95                       | GOODWIN, J.T., et al. (1993) "Incorporation of alkylthiol chains at C-5 of deoxyuridine" <i>Tetrahedron Lett.</i> 34(35):5549-5552.   |                |
|  | 96                       | GORLICK, R., et al. (December 1999) "Drug Resistance in Colon Cancer" <i>Semin. Oncol.</i> 26(6):606-611.   |                |
|  | 97                       | GOTTESMAN, M.M., et al. (1995) "Genetic analysis of the multidrug transporter" <i>Annu. Rev. Genet.</i> 29:607-649.   |                |
|  | 98                       | GRAHAM, D., et al. (1998) "DNA duplexes stabilized by modified monomer residues: synthesis and stability" <i>J. Chem. Soc. Perkin Trans. 1</i> :1131-1138.  |                |
|  | 99                       | GREM, J. L., et al. (April 1992) "Biochemical Modulation of Fluorouracil by Dipyrindamole: Predlinical and Clinical Experience" <i>Semin Oncol.</i> 19(2)(3):56-65.   |                |
|  | 100                      | GRIFFITH, D. A., et al. (1990) "Differential Inhibition of Nucleoside Transport Systems in Mammalian Cells by a New Series of Compounds Related to Lidoflazine and Mioflazine" <i>Biochem. Pharmacol.</i> 40(10):2297-2303.                                   |                |


*[Signature]* 11/17/03

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials   | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published  | T <sup>2</sup> |
|--|--------------------------|--|----------------|
|  | 101                      | GROS, P., et al. (1986) "Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells" <i>PNAS USA</i> 83:337-341.   |                |
|  | 102                      | GROS, P., et al. (1986) "Isolation and expression of a complementary DNA that confers multidrug resistance" <i>Nature</i> 323:728-7731.  |                |
|  | 103                      | GROS, P., et al. (1986) "Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins" <i>Cell</i> 47:371-380.  |                |
|  | 104                      | GUDKOV, A.V., et al. (1987) "Cloning and characterization of DNA sequences amplified in multidrug-resistant djungarian hamster and mouse cells" <i>Somat. Cell. Mol. Genet.</i> 13(6):609-619.   |                |
|  | 105                      | HAKIMELAHI, G.H., et al. (November 10, 1995) "Design, Synthesis and Structure-Activity Relationship of Novel Dinucleotide Analogs" 38(23):4648-4659.   |                |
|  | 106                      | HARDY, L.W., et al. (1987) "Atomic structure of thymidylate synthase: Target for rational drug design" <i>Science</i> 235:448-455.   |                |
|  | 107                      | HARRIS, M.P., et al. (1996) "Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein" <i>Cancer Gene Ther.</i> 3(2):121-130.  |                |
|  | 108                      | HASHIMOTO, Y., et al. (1987) "Simple separation of tritiated water and [ <sup>3</sup> H] deoxyuridine from [5- <sup>3</sup> H] deoxyuridine 5'-monophosphate in the thymidylate synthase assay" <i>Anal. Biochem.</i> 167:340-346.                             |                |
|  | 109                      | HENGSTSCHLÄGER, M., et al. (1996) "The role of p16 in the E2F-dependent thymidine kinase regulation" <i>Oncogene</i> 12:1635-1643.   |                |
|  | 110                      | HOBBS, F.W. (1989) "Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids" <i>J. Org. Chem.</i> 54:3420-3422.  |                |
|  | 111                      | HOLÝ, A., et al. (1999) "Structure-Antiviral Activity Relationship in the Series of Pyrimidine and Purine N-[2-(2-Phosphonomethoxy)ethyl] Nucleotide Analogues. 1. Derivatives Substituted at the Carbon Atoms of the Base" <i>J. Med. Chem.</i> 42:2064-2086. |                |
|  | 112                      | HORIKOSHI, T., et al. (1992) "Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction" <i>Can. Res.</i> 52:108-116.   |                |
|  | 113                      | HORN, D.M., et al. (1997) "Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria" <i>Antiviral Res.</i> 34:71-74.  |                |
|  | 114                      | HOSTETLER, K.Y., et al. (1997) "Enhanced oral absorption and antiviral activity of 1-o-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, <i>in vitro</i> " <i>Biochem. Pharmacol.</i> 53:1815-1822.               |                |
|  | 115                      | HOUE, T.A., et al., (1997) "Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction" <i>Tumor Biol.</i> 18:53-68.              |                |
|  | 116                      | HOWELL, S. B., et al. (June 15, 1989) "Comparison of the Synergistic Potentiation of Etoposide, Doxorubicin, and Vinblastine Cytotoxicity by Dipyridamole" <i>Cancer Res.</i> 49:3178-3183.  |                |
|  | 117                      | HSIAO, L.Y., et al. (1981) "Synthesis of 5'-thymidyl bis(1-aziridinyl) phosphinates as antineoplastic agents" <i>J. Med. Chem.</i> 24:887-889.   |                |
|  | 118                      | HUANG, W., et al. (1997) "Active site general catalysts are not necessary for some proton transfer reactions of thymidylate synthase" <i>Biochem.</i> 36:1869-1873.  |                |
|  | 119                      | HUDZIAK, R.M., et al. (1990) "Selection for transformation and <i>met</i> protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor $\alpha$ " <i>Cell Growth &amp; Differentiation</i> 1:129-134.  |                |
|  | 120                      | HUDZIAK, R.M., et al. (July 1988) "Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor $\alpha$ in NIH 3T3 cells" <i>PNAS USA</i> 85:5102-5106.  |                |
|  | 121                      | HUSAIN, I., et al. (January 15, 1994) "Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy" <i>Cancer Research</i> 54:539-546.       |                |
|  | 122                      | HUSAK, R., et al. (1998) "Pseudotumor of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient" <i>British J. Dermatol.</i> 139:118-121.  |                |
|  | 123                      | IMAI, K., et al. (1969) "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides" <i>J. Org. Chem.</i> 34(6):1547-1550.   |                |
|  | 124                      | JACKMAN, A.L., et al. (1995) "Folate-based thymidylate synthase inhibitors as anticancer drugs" <i>Annals of Oncology</i> 6:871-881.   |                |



### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials*   | Cite<br>No. <sup>1</sup>   | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup>        |
|---|--|---|-----------------------|
| <br>MAY 3 2007<br>DIPE<br>PATENT & TRADEMARK OFFICE | 125  | JACKMAN, A.L., et al. (1995) "Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation" <i>Anti-Cancer Drug Design</i> 10:573-589.  | TECH CENTER 1600/2900 |
|   | 126  | JOHNSTON, P.G. (1994) "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer" <i>J. Clin. Oncol.</i> 12(12):2640-2647.   |                       |
|   | 127  | JOHNSTON, P.G., et al. (1991) "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue" <i>Can. Res.</i> 51:6668-6676.   |                       |
|   | 128  | JONES, R.G., et al. (August 20, 1953) "New methods of synthesis of $\beta$ -aminoethylpyrazoles" <i>J. Am. Cancer Res.</i> 75:4048-4052.  |                       |
|   | 129  | KAMB, A., et al. (1998) "Cyclin-dependent kinase inhibitors and human cancer" <i>Curr. Top. Microbiol. Immunol.</i> 227:139-148.  |                       |
|   | 130  | KASHANI-SABET, M., et al. (October 15, 1988) "Detection of drug resistance in human tumors by <i>in vitro</i> enzyme amplification" <i>Can. Res.</i> 48:5775-5778.  |                       |
|   | 131  | KATKI, A.G., et al. (March 1998) " Prodrugs Activated by Thymidylate Synthase: Treatment of Tumors with Deoxyuridine Analogs" <i>Proc. Amer. Assoc. Cancer Res.</i> 39, Abstract No. 1275.  |                       |
|   | 132  | KLECKER, R.W., et al. (1994) "Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy- $\beta$ -D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells" <i>Mol. Pharmacol.</i> 46:1204-1209.        |                       |
|   | 133  | KNIGHTON, D.R., et al. (1994) "Structure and kinetic channeling in bifunctional dihydrofolate reductase-thymidylate synthase" <i>Nature Struct. Biol.</i> 1(3):186-194.   |                       |
|   | 134  | KOBAYASHI, H., et al. (November 1995) "Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors" <i>Jpn. J. Can. Res.</i> 86:1014-1018.  |                       |
|   | 135  | KODAMA, E., et al. (1996) "Evaluation of antiherpetic compounds using a gastric cancer cell line: Pronounced activity of BVDU against herpes simplex virus replication" <i>Microbiol. Immunol.</i> 40(5):359-363.   |                       |
|   | 136  | KRAJEWSKA, E., et al. (1982) "Pyrimidine ribonucleoside phosphorylase activity VS 5- and/or 6-substituted uracil and uridine analogues, including conformational aspects" <i>Biochem. Pharmacol.</i> 31(6):1097-1102.   |                       |
|   | 137  | KRAUPP, M., et al. (1995) "Membrane Transport of Nucleobases: Interaction with Inhibitors" <i>Gen. Pharmacol.</i> 26(6):1185-1190.  |                       |
|   | 138  | KUMAR, A., et al. (1990) "Synthesis and Biological Evaluation of Some Cyclic Phosphoramidate Nucleoside Derivatives" <i>J. Med. Chem.</i> 33(9):2368-2735.  |                       |
|   | 139  | KUNDU, N.G. (1993) "Synthesis and biological activities of [E]-5-(2-acylviny)l uracils" <i>Eur. J. Med. Chem.</i> 28:473-479.   |                       |
|   | 140  | KUROBOSHI, M., et al. (1991) "A facile synthesis of difluoromethylene compounds by oxidative fluorodesulfurization of dithioacetals using tetrabutylammonium dihydrogentrifluoride and N-halo compounds" <i>SYNLETT</i> :909-910.                             |                       |
|   | 141  | KUROBOSHI, M., et al. (1994) "A facile synthesis of $\alpha$ , $\alpha$ -difluoroalkyl ethers and carbonyl fluoride acetals by oxidative desulfurization-fluorination" <i>SYNLETT</i> :251-252.   |                       |
|   | 142  | LACKEY, D. B., et al. (2001) "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase" <i>Biochem. Pharmacol.</i> 61:179-189.  |                       |
|   | 143  | LAM, K.S. (1997) "Application of combinatorial library methods in cancer research and drug discovery" <i>Anticancer Drug Design</i> 12:145-167.   |                       |
| 144   | LARSSON, P.A., et al. (1996) "Thymidylate Synthase in Advanced Gastrointestinal and Breast Cancers" <i>Acta Oncological</i> 35(4):469-472.   |   |                       |
| 145   | LASIC, D.D. (April 11, 1996) "Doxorubicin in sterically stabilized liposomes" <i>Nature</i> 380:561-562.   |   |                       |
| 146   | LEE, Y.L., et al. (1997) "Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein" <i>Exp. Cell Res.</i> 234:270-276.   |   |                       |
| 147   | LEHMAN, N. L., et al. (2000) "Modulation of RTX cytotoxicity by thymidine and dipyridamole <i>in vitro</i> : implications for chemotherapy" <i>Cancer Chemother. Pharmacol.</i> 45:142-148.  |   |                       |
| 148   | LEICHMAN, C. G., et al. (October 1997) "Quantitation of Intratumoral Thymidylate Synthase Expression Predicts for Disseminated Colorectal Cancer Response and Resistance to Protracted-Infusion Fluorouracil and Weekly Leucovorin" <i>J. Clin. Oncol.</i> 15(10):3223-3229. |   |                       |
| 149   | LENZ, H.J., et al. (May 1998) "p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site" <i>Clinical Cancer Research</i> 4:1227-1234.  |   |                       |


*Handwritten signature* 11/17/03

MAY 31 2002



### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|--------------------|-----------------------|---|----------------|



|  |     |   |  |
|--|-----|---|--|
|  | 150 | LES, A., et al. (1998) "Modeling of reaction steps relevant to deoxyuridylate (dUMP) enzymatic methylation and thymidylate synthase mechanism-based inhibition" <i>Journal of Biomolecular Structure &amp; Dynamics</i> 15(4):703-715.  |  |
|  | 151 | LEWIS, J.G., et al. (April 1996) "A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA" <i>PNAS USA</i> 93:3176-3181.  |  |
|  | 152 | LI, W., et al. (1995) "Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines" <i>PNAS USA</i> 92:10436-10440.  |  |
|  | 153 | LIN, W.Y., et al. (1997) "Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases" <i>Eur. J. Nucl. Med.</i> 24(6):590-595.                 |  |
|  | 154 | LIVAK, K.J., et al. (1992) "Detection of single base differences using biotinylated nucleotides with very long linker arms" <i>Nucl. Acids Res.</i> 20(18):4831-4837.   |  |
|  | 155 | LIVINGSTONE, L.R., et al. (1992) "Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53" <i>Cell</i> 70:923-935.   |  |
|  | 156 | LÖNN, U., et al. (1996) "Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy" <i>Cancer</i> 77(1):107-112.  |  |
|  | 157 | LOOK, K.Y., et al. (1997) "Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma" <i>Anticancer Res.</i> 17:2353-2356.   |  |
|  | 158 | LOVEJOY, E.A., et al. (1997) "Animal models and the molecular pathology of cancer" <i>J. Pathol.</i> 181:130-135.   |  |
|  | 159 | MADEC, A., et al. (1998) "Some characteristics of fetal and adult isoenzymes of thymidine kinase in human breast cancers" <i>Bull. Cancer</i> 75:187-194.   |  |
|  | 160 | MADER, R.M., et al. (1998) "Resistance to 5-fluorouracil" <i>Gen. Pharma.</i> 31(5):661-666.  |  |
|  | 161 | MAHONY, C., et al. (March 1982) "Dipyridamole Kinetics" <i>Clin. Pharmacol. Ther.</i> 31(3):330-338.  |  |
|  | 162 | MASTERS, J.N., et al. (1983) "The nucleotide sequence of the c DNA coding for the human dihydrofolic acid reductase" <i>Gene</i> 21:59-63.  |  |
|  | 163 | MCGUIGAN, C. (1992) "Aryl phosphate derivative of AZT retain activity HIV1 in cell lines which are resistant to the action of AZT" <i>Antiviral Res.</i> 17:311-321.  |  |
|  | 164 | MCGUIGAN, C. (1993) "Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT" <i>J. Med. Chem.</i> 36:1048-1052.   |  |
|  | 165 | MCGUIGAN, C. (1996) "Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite" <i>J. Med. Chem.</i> 39:1748-1753.                    |  |
|  | 166 | MCGUIGAN, C. (1998) "Synthesis and evaluation of some masked phosphate esters of the anti-herpetic drug 882C (netivudine) as potential antiviral agents" <i>Antiviral Chem. Chemother.</i> 9:187-197.                                   |  |
|  | 167 | MCGUIGAN, C., et al. (1994) "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase" <i>FEBS Lett.</i> 351:11-14.  |  |
|  | 168 | MCINTEE, E.J., et al. (1997) "Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs" <i>J. Med. Chem.</i> 40:3323-3331.  |  |
|  | 169 | MCKAY, G.A., et al. (1994) "Broad spectrum aminoglycoside phosphotransferase type III from <i>Enterococcus</i> : Overexpression, purification, and substrate specificity" <i>Biochem</i> 33:6936-6944.                                  |  |
|  | 170 | MEDEN, H., et al. (1994) "Elevated serum Levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy" <i>J. Cancer Res. Clin. Oncol.</i> 120:378-381.   |  |
|  | 171 | MEIER, C., et al. (1997) "ADA-bypass by lipophilic cyclosal-ddAMP pro-nucleotides a second example of the efficiency of the cyclosal-concept" <i>Bioorg. &amp; Med. Chem. Lett.</i> 7(12):1577-1582.                                    |  |
|  | 172 | MEIER, C., et al. (1997) "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) – a new pro-nucleotide approach <sup>1</sup> " <i>Bioorg. &amp; Med. Chem. Lett.</i> 7(2):99-104.                           |  |
|  | 173 | MEIER, C., et al. (1997) "Cyclosal-pro-nucleotides: the design and biological evaluation of a new class of lipophilic nucleotide prodrugs" <i>International Antiviral News</i> 5(10):183-185.   |  |
|  | 174 | MELTON, R.G., et al. (February 21, 1996) "Antibody-enzyme conjugates for cancer therapy" <i>J. Natl. Canc. Institute</i> 88(3/4):153-165.   |  |
|  | 175 | MOBASHERY, S., et al (June 15, 1986) "Reactions of <i>Escherichia coli</i> TEM $\beta$ -lactamase with cephalothin and with C <sub>10</sub> -dipeptidyl cephalosporin esters" <i>J. Biol. Chem.</i> 261(17):7879-7887.                  |  |
|  | 176 | MOBASHERY, S., et al. (1986) "Conscripting $\beta$ -lactamase for use in drug delivery. Synthesis and biological activity of a cephalosporin C <sub>10</sub> -ester of an antibiotic dipeptide" <i>J. Am. Chem. Soc.</i> 108:1686-1688. |  |

11/17/03

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
|-----------------------|--------------------------|---|----------------|

|  |     |   |  |
|--|-----|---|--|
|  | 177 | MONTFORT, W.R., et al. (1997) "Thymidylate synthase: Structure, inhibition, and strained conformations during catalysis" <i>Pharmacol. Ther.</i> 76(1-3):29-43.   |  |
|  | 178 | MONTGOMERY, J.A., et al. (1979) "Phosphonate analogue of 2'-deoxy-5-fluorouridylic acid" <i>J. Med. Chem.</i> 22(1):109-111.  |  |
|  | 179 | MORGAN, A.S., et al. (June 15, 1998) "Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase" <i>Cancer Res.</i> 58:2568-2575.   |  |
|  | 180 | MURAKAMI, Y., et al. (1998) "Accumulation of genetic alterations and their significance in each primary human cancer and cell line" <i>Mutat. Res.</i> 400(1-2):421-437.  |  |
|  | 181 | NAESENS, L., et al. (April 1997) "Anti-HIV Activity and Metabolism of Phosphoramidate Derivatives of D4T-MP with Variations in the Amino Acid Moiety" <i>Poster Session 1, The Tenth International Conference on Antiviral Research, Hotel Nikko, Atlanta, GA, April 6-11, 1997; published in Antiviral Research</i> 34(2):A54 (Abstract 40). |  |
|  | 182 | NAKANO, T., et al. (1994) "Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis" <i>Biochem.</i> 33:9945-9952.  |  |
|  | 183 | NEGISHI, K., et al. (1996) "Enhancement of N4-aminocytidine-induced mutagenesis by Ni++ ion" <i>Nucl. Acids Symposium</i> 35:137-138.   |  |
|  | 184 | NELSON, J. A., et al. (June 1984) "Potentiation of Methotrexate Toxicity by Dipyridamole" <i>Cancer Res.</i> 44:2493-2496.  |  |
|  | 185 | NOOTER, K., et al. (1996) "Molecular mechanisms of multidrug resistance in cancer chemotherapy" <i>Pathol. Res. Pract.</i> 192:768-780.   |  |
|  | 186 | OSAKI, M., et al. (1997) "5-fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: Role of the p53 gene" <i>Apoptosis</i> 2:221-226.   |  |
|  | 187 | OSHIRO, Y., et al. (1992) "Genotoxic properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)" <i>Fund. Appl. Toxicol.</i> 18:491-498.   |  |
|  | 188 | PARADISO, A., et al. (2000) "Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients" <i>British J. of Cancer</i> 82(3):560-567.   |  |
|  | 189 | PARDO, E.G., et al. (1987) "The incorporation of deoxyuridine monophosphate into DNA increases the sister-chromatid exchange yield" <i>Exp. Cell Res.</i> 168:507-517.  |  |
|  | 190 | PARK, N.-H., et al. (June 1982) "Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice" <i>J. Infectious Diseases</i> 145(6):909-913.  |  |
|  | 191 | PEDERSEN-LANE, J., et al. (1997) "High-level expression of human thymidylate synthase" <i>Protein Expression and Purification</i> 10:256-262.   |  |
|  | 192 | PEGRAM, M.D., et al. (1997) "The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells" <i>Oncogene</i> 15:537-547.  |  |
|  | 193 | PERRY, K.M., et al. (1990) "Plastic adaptation toward mutations in proteins: Structural comparison of thymidylate synthases" <i>Proteins</i> 8:315-333.   |  |
|  | 194 | PESTALOZZI, B.C., et al. (1997) "Prognostic importance of thymidylate synthase expression in early breast cancer" <i>J. Clin. Oncol.</i> 15(5):1923-1931.   |  |
|  | 195 | PETERS, G.J., et al. (1995) "Thymidylate synthase and drug resistance" <i>Eur. J. Cancer</i> 31A(7/8):1299-1305.  |  |
|  | 196 | PHELPS, M.E., et al. (1980) "Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates" <i>J. Med. Chem.</i> 23:1229-1232.   |  |
|  | 197 | PLUTA, J., et al. (1999) "Synthesis and biological properties of 4-hydroxy, 4-thio-5-pyrimidine derivatives" <i>Boll. Chim. Farm.</i> 138(1):30-33.   |  |
|  | 198 | PUPA, S.M., et al. (1993) "The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage" <i>Oncogene</i> 8:2917-2923.  |  |
|  | 199 | RAMU, N., et al. (1989) "Circumvention of Adriamycin Resistance by Dipyridamole Analogues: A structure-activity relationship Study" <i>Int. J. Cancer</i> 43:487-491.   |  |
|  | 200 | ROBERTS, D.W. (1966) "An isotopic assay for thymidylate synthetase" <i>Biochem.</i> 5(11):3546-3548.  |  |
|  | 201 | ROBINS, M.J., et al. (1981) "Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides" <i>Tetrahedron Lett.</i> 22:421-424.   |  |
|  | 202 | ROBINS, M.J., et al. (1982) "Nucleic acid related compounds. 38. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and p-toluyyl-protected nucleosides" <i>Can. J. Chem.</i> 60:554-557.   |  |

TECH CENTER 1600/2600

MAY 31 2002

OIP  
MAY 31 2002  
REMARK OFFICE

*[Handwritten Signature]* 11/17/03

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPS and LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T <sup>2</sup> |
|----------------------|--------------------------|--|----------------|
|----------------------|--------------------------|--|----------------|

|  |     |  |  |
|--|-----|--|--|
|  | 203 | ROBINS, M.J., et al. (1983) "Nucleic acid related compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derivated 5-substituted uracil bases and nucleosides" <i>J. Org. Chem.</i> <b>48</b> :1854-1862.  |  |
|  | 204 | ROGULSKI, K.R., et al. (January 1, 1997) "Glioma cells transduced with an <i>Escherichia coli</i> CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity" <i>Hum. Gene Ther.</i> <b>8</b> :73-85.   |  |
|  | 205 | ROMAIN, S., et al. (1995) "Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer" <i>Int. J. Cancer</i> <b>61</b> :7-12.   |  |
|  | 206 | RONINSON, I.B., et al. (1984) "Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells" <i>Nature</i> <b>309</b> :626-628.  |  |
|  | 207 | ROONEY, P. H., et al. (November 15, 1998) "Comparative Genomic Hybridization Analysis of Chromosomal Alterations Induced by the Development of Resistance to Thymidylate Synthase Inhibitors" <i>Cancer Res.</i> <b>58</b> :5042-5045.                                 |  |
|  | 208 | ROTH, J.A., et al. (1999) "p53 tumor suppressor gene therapy for cancer" <i>Oncology</i> <b>13</b> (10)(5):148-154.  |  |
|  | 209 | RUTH, J.L., et al. (1978) "C-5 substituted pyrimidine nucleosides. 1. Synthesis of C-5 allyl, propyl, and propenyl uracil and cytosine nucleosides via organopalladium intermediates" <i>J. Org. Chem.</i> <b>43</b> (14):2870-2876.                                   |  |
|  | 210 | SABOULARD, D., et al. (1999) "Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine" <i>Mol. Pharmacol.</i> <b>56</b> :693-704.  |  |
|  | 211 | SANTI, D.V. (February 1980) "Perspectives on the design and biochemical pharmacology of inhibitors of thymidylate synthetase" <i>J. Med. Chem.</i> <b>23</b> (2):103-111.  |  |
|  | 212 | SASTRY, J.K., et al. (1992) "Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection" <i>Mol. Pharmacol.</i> <b>41</b> :441-445.   |  |
|  | 213 | SAUTER, G., et al. (1993) "Heterogeneity of <i>erbB-2</i> gene amplification in bladder cancer" <i>Cancer Res.</i> <b>53</b> :2199-2203.   |  |
|  | 214 | SCHIFFER, C.A., et al. (1995) "Crystal structure of human thymidylate synthase: A structural mechanism for guiding substrates into the active site" <i>Biochem.</i> <b>34</b> :16279-16287.  |  |
|  | 215 | SCHIMKE, R.T. (1988) "Gene amplification in cultured cells" <i>J. Biol. Chem.</i> <b>263</b> (13):5989-5992.   |  |
|  | 216 | SCHMOLL, H.-J. (1994) "Colorectal carcinoma: Current problems and future perspectives" <i>Ann. Oncol.</i> <b>5</b> (3):115-121.  |  |
|  | 217 | SEGOVIA, M. (1994) " <i>Leishmania</i> gene amplification: A mechanism of drug resistance" <i>Annals Tropical Med. Parasitol.</i> <b>88</b> (2):123-130.   |  |
|  | 218 | SHEPARD, H.M., et al. (1988) "Resistance of tumor cells to tumor necrosis factor" <i>J. Clin. Immunol.</i> <b>8</b> (5):333-341.   |  |
|  | 219 | SIMON, S.M., et al. (April 1994) "Cell biological mechanisms of multidrug resistance in tumors" <i>PNAS USA</i> <b>91</b> :3497-3504.  |  |
|  | 220 | SINGH, J., et al. (1993) "Studies on the preparation and isomeric composition of <sup>186</sup> Re-pentavalent rhenium dimercaptosuccine acid complex" <i>Nucl. Med. Commun.</i> <b>14</b> :197-203.   |  |
|  | 221 | SLAMON, D.J., et al. (1987) "Human breast cancer: Correlation of relapse and survival with amplification of the <i>HER-2/neu</i> oncogene" <i>Science</i> <b>235</b> :177-182.   |  |
|  | 222 | SLAMON, D.J., et al. (1989) "Studies of the <i>HER-2/neu</i> proto-oncogene in human breast and ovarian cancer" <i>Science</i> <b>244</b> :707-712.  |  |
|  | 223 | SMITH, K.A., et al. (1995) "Regulation and mechanisms of gene amplification" <i>Phil. Trans. R. Soc. Lond.</i> <b>347</b> :49-56.  |  |
|  | 224 | SNYDMAN, D.R., et al. (1996) "Analysis of trends in antimicrobial resistance patterns among clinical isolates of <i>Bacteroides fragilis</i> group species from 1990 to 1994" <i>Clinical Infectious Diseases</i> <b>23</b> (Suppl. 1):S54-S65.                        |  |
|  | 225 | STASCHKE, K.A., et al. (1994) "The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl-4-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell" <i>Antiviral Res.</i> <b>23</b> :45-61. |  |
|  | 226 | STOUT, T.J., et al. (1999) "Structure-based design of inhibitors specific for bacterial thymidylate synthase" <i>Biochem.</i> <b>38</b> :1607-1617.  |  |
|  | 227 | STÜHLINGER, M., et al. (1994) "Clinical therapy and <i>HER-2</i> oncogene amplification in breast cancer: Chemo-vs radiotherapy" <i>J. Steroid Biochem. Mol. Biol.</i> <b>49</b> (1):39-42.  |  |
|  | 228 | SUGARMAN, B.J., et al. (1985) "Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro" <i>Science</i> <b>230</b> (4728):943-945.   |  |

|  |              |   |   |              |                        |            |
|--|--------------|---|---|--------------|------------------------|------------|
| Sheet  | 10           | of  | 1 | MAY 3 0 2002 | Attorney Docket Number | NB 2019.00 |
| <b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b> |              |   |   |              |                        |            |
| Examiner<br>Initials*                                    | Cite<br>No.¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published |   |              |                        | T²         |

|     |   |
|-----|---|
| 229 | SUKI, S., et al. (1995) "Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase" <i>Leukemia and Lymphoma</i> 18:87-92.  |
| 230 | SUKUMAR, S., et al. (1990) "Specific patterns of oncogene activation in transplacentally induced tumors" <i>PNAS USA</i> 87:718-722.  |
| 231 | TAKEISHI, K., et al. (1985) "Nucleotide sequence of a functional cDNA for human thymidylate synthase" <i>Nucl. Acid Res.</i> 13(6):2035-2043.   |
| 232 | TANNOCK, I.F. (December 1996) "Treatment of cancer with radiation and drugs" <i>J. Clin. Oncol.</i> 14(12):3156-3174.   |
| 233 | TEH, B.T., et al. (1999) "Tumor suppressor genes (TSG)" <i>Anticancer Research</i> 19:4715-4728.  |
| 234 | TENNANT, B.C., et al. (1998) "Antiviral activity and toxicity of flaridine in the woodchuck model of hepatitis B virus infection" <i>Hepatol.</i> 28(1):179-191.  |
| 235 | TOLSTIKOV, V.V., et al. (1997) "Synthesis and DNA duplex stabilities of oligonucleotides containing C-5-(3-methoxypropynyl)-2'-deoxyuridine residues" <i>Nucleosides &amp; Nucleotides</i> 16(3):215-225.   |
| 236 | TROUTNER, D.E. (1987) "Chemical and physical properties of radionuclides" <i>Nucl. Med. Biol.</i> 14(3):171-176.  |
| 237 | TSAVARIS, N., et al. (1990) "Multimodal Biochemical Modulation of 5-Fluorouracil Activity in Advanced Colorectal Cancer with Allopurinol, Folinic Acid and Dipyridamol" <i>J. Chemother.</i> 2(2):123-126.  |
| 238 | UBEDA, M., et al. (1997) "The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during fas-induced apoptosis" <i>J. Biol. Chem.</i> 272(31):19562-19568.  |
| 239 | VALETTE, G., et al. (1996) "Decomposition pathways and <i>in vitro</i> HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5'-monophosphoates" <i>J. Med. Chem.</i> 39:1981-1990                     |
| 240 | VAN DE VIJVER, M., et al. (1987) "Amplification of the <i>neu</i> ( <i>c-erbB-2</i> ) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked <i>c-erbA</i> oncogene" <i>Mol. Cell. Biol.</i> 7(5):2019-2023. |
| 241 | VOLM, M., et al. (1992) "Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase- $\pi$ in human lung tumors" <i>Cancer</i> 70(4):764-769.                                     |
| 242 | WADLER, S., et al. (September 1987) "Phase II Trial of Oral Methotrexate and Dipyridamole in Colorectal Carcinoma" <i>Cancer Treat. Rep.</i> 71(9):821-824.   |
| 243 | WAHBA, A.J., et al. (March 1961) "Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate" <i>J. Biol. Chem.</i> 236(3):PC11-PC12.   |
| 244 | WALLIS, M.P., et al. (1999) "Synthesis and anti-HIV activity of C4-modified pyrimidine nucleosides" <i>Il Farmaco</i> 54:83-89.   |
| 245 | WANG, S., et al. (1996) "Identification and characterization of Ich-3, a member of the interleukin-1 $\beta$ converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE" <i>J. Biol. Chem.</i> 271(34):20580-20587.  |
| 246 | WATAYA, Y., et al. (April 1979) " <i>trans</i> -5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridylate: A mechanism-based inhibitor of thymidylate synthetase" <i>J. Med. Chem.</i> 22(4):339-340.  |
| 247 | WETTERGREN, Y., et al. (1994) "Drug-specific rearrangements of chromosome 12 in hydroxyurea-resistance mouse SEWA cells: Support for chromosomal breakage model of gene amplification" <i>Somatic Cell Mol. Genet.</i> 20(4):267-285.                                 |
| 248 | WHALEN, R., et al. (1998) "Human glutathione S-transferases" <i>Seminars in Liver Disease</i> 18(4):345-358.  |
| 249 | WILLSON, J. K.V., et al. (October 1, 1988) "Phase I Clinical Trial of a Combination of Dipyridamole and Acivicin Based Upon Inhibition of Nucleoside Salvage" <i>Cancer Res.</i> 48:5585-5590.  |
| 250 | WRIGHT, AMP, et al. (2000) "Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemia lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport" <i>Leukemia</i> 14:52-60.                      |
| 251 | YEN, Y., et al. (July 15, 1994) "Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine" <i>Cancer Res.</i> 54:3686-3691.  |
| 252 | YIN, Y., et al. (1992) "Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles" <i>Cell</i> 70:937-948.   |
| 253 | ZEID, I.F., et al. (1999) "Synthesis of new thiolated acyclonucleosides with potential anti-HBV activity" <i>Nucleosides &amp; Nucleotides</i> 18(1):95-111.  |

|  |                          |   |    |                        |                |
|--|--------------------------|---|----|------------------------|----------------|
| Sheet  | 11                       | of  | 11 | Attorney Docket Number | NB 2019.00     |
| <b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b> |                          |   |    |                        |                |
| Examiner<br>Initials*                                    | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published |    |                        | T <sup>2</sup> |

|           |     |  |  |
|-----------|-----|--|--|
| <i>pr</i> | 254 | ZHOU, Q., et al. (1997) "Target protease specificity of the viral serpin CrmA" <i>J. of Biol. Chem.</i> 272(12):7797-7800. |  |
|-----------|-----|--|--|

|                         |                    |                    |          |
|-------------------------|--------------------|--------------------|----------|
| Examiner's<br>Signature | <i>[Signature]</i> | Date<br>Considered | 11/17/03 |
|-------------------------|--------------------|--------------------|----------|

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

